Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) EPS (Basic) (2016 - 2025)

Vycor Medical has reported EPS (Basic) over the past 16 years, most recently at -$0.0 for Q4 2025.

  • Quarterly EPS (Basic) fell 816.87% to -$0.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.01 through Dec 2025, up 50.0% year-over-year, with the annual reading at -$0.01 for FY2025, 0.0% changed from the prior year.
  • EPS (Basic) was -$0.0 for Q4 2025 at Vycor Medical, up from -$0.0 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.0 in Q2 2023 and troughed at -$0.02 in Q4 2021.
  • The 5-year median for EPS (Basic) is -$0.0 (2023), against an average of -$0.01.
  • Year-over-year, EPS (Basic) tumbled 896.61% in 2022 and then skyrocketed 332.66% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.02 in 2021, then soared by 81.62% to -$0.0 in 2022, then rose by 22.35% to -$0.0 in 2023, then soared by 92.82% to -$0.0 in 2024, then tumbled by 816.87% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's EPS (Basic) are -$0.0 (Q4 2025), -$0.0 (Q3 2025), and $0.0 (Q2 2025).